Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
about
Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Factors that influence patient response to requests to change to a unified restrictive formularyMedication use in the transition from hospital to home.Evaluation of discharge medication orders following automatic therapeutic substitution of commonly exchanged drug classes.ePrescribing: Reducing Costs through In-Class Therapeutic Interchange.Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population.
P2860
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@ast
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@en
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@nl
type
label
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@ast
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@en
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@nl
prefLabel
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@ast
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@en
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@nl
P2093
P1476
Prevalence and cost savings of therapeutic interchange among U.S. hospitals.
@en
P2093
Jill M Schachtner
Joseph J Medicis
Nancy Newman
Ronald Speizer
Roy Guharoy
P304
P577
2002-03-01T00:00:00Z